ubrogepant

FDA Drug Profile — UBRELVY

Drug Details

Generic Name
ubrogepant
Brand Names
UBRELVY
Application Number
NDA211765
Sponsor
Ubrogepant
NDC Codes
5
Dosage Forms
POWDER, TABLET
Routes
ORAL
Active Ingredients
UBROGEPANT

Indications and Usage

1 INDICATIONS AND USAGE UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. ( 1 )